Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) disorder in the community and clinical practice. The prevalence of IBS in Asian communities varies from 2.9% to 15.6%. 1 The pathogenesis of IBS is largely unknown. However, abnormal gut motility, dysbiosis, food intolerance such as lactose intolerance, visceral hypersensitivity, low-grade inflammation and abnormal brain-gut interaction have been incriminated in its pathogenesis. 2 High degree of concordance among monozygotic twin and familial aggregation suggested a role of genetic factor in pathogenesis of IBS. 3 Though some experts suggested that familial aggregation might be explained by learned behavior, 4 contribution of genetic factors is being explored in multiple studies in the recent literatures. How do the genetic factors influence occurrence of IBS? IBS is a multi-factorial polygenic disorder. Since gut motility, visceral sensation, degree of inflammation in response to microbes in the gut, food intolerance such as lactose intolerance and brain-gut interaction are all mediated by neuro-peptides, hormones and cytokines and various other proteins, which are transcribed from different genes, alteration in these genes may lead to alteration in these physiological processes. 5 Several studies found association between polymorphisms in various genes such as serotonin transporter (SERT or SLC6A4), α 2 adrenergic receptor, cytokine and G-protein genes and IBS. [6] [7] [8] [9] Genetic variations in α 2 adrenergic receptor may influence visceral sensation in patients with IBS. The α 2c Del 322-325 and α 2c −1291C＞G polymorphisms result in reduced pre-synaptic α 2 adrenoceptor function, and norepinephrine released from the pre-synaptic nerve endings is not effectively inactivated by re-uptake and subsequent monoamine oxidation. 10 Increased synaptic norepinephrine may inhibit cholinergic enteric motor neurones, reducing GI motility. In a study from USA, α 2c Del 322-325 deletion polymorphism, which results in loss of four amino acids (Gly-Ala-Gly-Pro) at positions 322-325, was found associated with constipation predominant IBS (IBS-C). 10 In another study from India, α 2a −1291C＞G was associated with diarrhea predominant IBS (IBS-D), but not with IBS-C. 7 A common polymorphism in Catechol-O-methyltransferase, which is known to cause valine substitution to methionine causing altered enzyme activity, was found to be associated with IBS. 11 Cannabinoid receptors modulate a variety of GI functions, including pain modulation, inflammation, and gastric and colonic motility. 12 The gene that codes for cannabinoid receptor 1 (CNR1) contains a polymorphic (AAT)n triplet repeat in the 3-flanking region of the CNR1 gene. Expression of this gene is inversely proportional to the number of AAT repeats. 13 In a study from Korea, this polymorphic (AAT)n triplet repeat of the (CNR1) gene is related to IBS and severity of abdominal pain among them. 12 Low-grade inflammation has been implicated in the pathophysiology of IBS. In a meta-analysis on 5 studies that investigated IL-10 (an anti-inflammatory cytokine) 1082G/A, TGF-β1 (anti-inflammatory) +869T/C and +915G/C and TNF (pro-inflammatory) 308G/A polymorphisms in patients with IBS and controls were included. High producer of anti-inflammatory cytokine IL-10 (1082) was associated with a reduced risk of IBS. 8 Though no association was found between TNF (308G/A) genotypes and IBS, in sub-group analysis of the Asian studies, there was an association between TNF (308 G/A and G/G) genotypes and IBS. 8 A study from our centre on IL-1 receptor antagonist (IL-1RA) polymorphism showed that genotype 1/1 (over-producer of IL1-RA) was infrequent among patients than controls.
14 Cholecystokinin (CCK) is released by endocrine cells within the duodenal and jejunal mucosa in response to products of protein and fat digestion. Therapeutic blockade of CCK1 receptors (CCK1R) may stimulate gut motility and may reduce colonic transit time in patients with IBS-C. 15 A polymorphism in CCK1R gene (779T＞C) was found to be associated with slower gastric emptying among patients with IBS-C. 16 This suggests that, compared with the 779T variant, the 779C substitution results in an increased response to endogenous CCK, prolonging gastric emptying. Serotonin or 5-hydroxytryptamine (5-HT) is an important molecule for stimulating GI motility, secretion and enhancing visceral sensation. Serotonergic neurotransmission is regulated by SERT, which transports the serotonin released into the synaptic cleft back to the pre-synaptic nerve endings. Polymorphisms in SERT gene, encoding the transporter protein, affect transcriptional activity and influence 5-HT re-uptake efficiency. The 5-HT transporter-linked polymorphic region (5-HTTLPR) comprises a repetitive sequence with an insertion-deletion variation. 6 In a meta-analysis on 25 studies including 3,443 patients with IBS and 3,359 controls, L/L genotype was demonstrated to be a risk factor for the development of IBS-C. In the analysis of different ethnicities, L allele and L/L genotype were significantly associated with increased IBS-C risk in the East Asian population, but not in the Caucasian population. 17 In a study from our center on SLC6A4 polymorphism of SERT showed that deletion/deletion genotype of SLC6A4 polymorphism was associated with IBS, particularly IBS-D. 6 G-protein beta-3 subunit gene (GNβ3), C825T polymorphism alters intra-cellular signal transduction, which may lead to motor or sensory abnormalities of the GI tract. 18 One study aimed to show association between GNβ3 C825T among Korean children with IBS. They showed that C/C genotype of GNβ3 C825T was more common in patients with IBS than controls. Also, C/C genotype was common in IBS-D, and the T/T genotype was common in IBS-C. 19 However, a meta-analysis on seven case-control studies including 1,085 patients with IBS and 1,695 healthy controls did not show any association between GNβ3 C825T polymorphism and IBS. 9 The current issue of the journal presented a study on 99 patients with IBS and 171 healthy controls evaluating a possible association between SLC6A4 5-HTTLPR, ADRA2A 1291C＞ G, GNB3 825C＞T, CCK1R intron 779T＞C, and TRPV1 945G＞C polymorphisms and IBS. 20 The authors showed that However, GNB3 825C＞T, CCK1R intron 779T＞C and TRPV1 945G＞C polymorphism did not show significant differences between patients and controls. Also, patients with IBS-C showed reduced level of serum serotonin compared to controls and IBS-D patients (50.2 ng/mL vs. 69.0 ng/mL and 92.9 ng/mL, P = 0.017 and P = 0.001, respectively). Though this is an important step towards attempting to understand genetic basis of IBS, it suffers from limitation due to inadequate power resulting from relatively small sample size. Moreover, since the authors studied several genetic polymorphism, multivariate analysis would have helped us to under-stand interplay between various genetic factors and independent effect of each gene. Moreover, since IBS is a multi-factorial polygenic disorder, relative effect of environmental factors in addition to genetic factors would have thrown more light into pathogenesis of IBS. Though measurement of serotonin level has given an important insight into the pathogenesis, therapeutic manipulation of which is expected to help managing these patients, estimation of the serum sample rather than tissue is a limitation of this study. However, in spite of these limitations, the present study is an important step towards understanding the genetic basis of IBS; it reminds us the famous saying by Robert Fulghum, an American author, "I believe that imagination is stronger than knowledge. That myth is more potent than history. That dreams are more powerful than facts…."
